Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

42004 Scalp, Eyebrow, and Eyelash Hair Regrowth with Continued Ritlecitinib Treatment among Patients with Alopecia Areata Without Target Efficacy Response at Week 24: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study

Maryanne M. Senna,Seth Forman,Lindsey A. Bordone,P. de la Cueva Dobao,Robert Wołk,Samuel H. Zwillich,Fan Zhang,Haytham Mohamed Ahmed,Liza Takiya

Journal of the American Academy of Dermatology（2023）

Cited 0|Views0
No score
Abstract
Background: This post hoc analysis of the ALLEGRO phase 2b/3 study (NCT03732807) assessed response to ritlecitinib, an oral JAK3/TEC inhibitor, between Weeks 28-48 among patients with alopecia areata (AA) who did not meet target efficacy response criteria at Week 24.
More
Translated text
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined